In a recent issue of *Critical Care*, Murugan and colleagues drew the conclusion that, among critically ill patients with ≥ 5% fluid overload, the patients with net ultrafiltration (UF^NET^) exceeding 25 ml/kg/day compared with those below 20 ml/kg/day had a lower 1-year risk-adjusted mortality \[[@CR1]\]. The definition of UF^NET^ in their paper was calculated as the difference between the volume of ultrafiltration and substitution fluids. Furthermore, for patients receiving continuous venovenous hemodiafiltration and slow continuous ultrafiltration, UF^NET^ corresponded to the volume removed. However, for patients on renal replacement therapy, spontaneous urine output (UO) and intravenous fluid via the peripheral vein (Fiv) should also be taken into account for the estimation of total UF^NET^. Thus, the total net ultrafiltration should be adjusted by UF^NET^ + UO -- Fiv. We believe that this adjustment achieves a more accurate parameter to reflect the hemodynamic status of patients in clinical practice.

In addition, as shown in their study, the imbalance was observed for the mean arterial pressure among three different levels of UF^NET^ intensity in all the patients receiving renal replacement therapy and the subset of patients receiving continuous renal replacement therapy (*P* \< 0.001). It is well recognized that low blood pressure is a common complication during renal replacement therapy and is strongly associated with illness severity \[[@CR2]\]. Low blood pressure will trigger an adjustment for total ultrafiltration volume. Thus, blood pressure appears to be a confounding factor to the results. Although adjusted by statistical models, it is better to re-analyze the association between UF^NET^ intensity and mortality by categorized blood pressure levels to provide stronger evidence.

Fiv

:   Fluid infusion by peripheral vein

UF^NET^

:   Net ultrafiltration

UO

:   Urine output

See related research by Murugan et al., <https://ccforum.biomedcentral.com/articles/10.1186/s13054-018-2163-1>.
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We would like to thank Dr. Li and colleagues for their thoughtful letter regarding our article \[[@CR1]\]. They propose that we should account for urine output as well as the intravenous fluids administered in estimating the total UF^NET^ volume. However, we would like to clarify that the purpose of our study was to examine whether there was an independent association between the process of care variable, UF^NET^ intensity, and risk-adjusted 1-year mortality. Thus, we specifically did not include the urine output and the intravenous fluids in the calculation of UF^NET^ (exposure variable) as it would confound the assessment of the relative contribution of UF^NET^ intensity on the outcome.

In our study, all intravenous fluids administered, as well as fluid losses including the urine output, were part of the input and output equation to calculate the severity of fluid overload before initiation of renal replacement therapy as well as the cumulative fluid balance during renal replacement therapy (as outlined in Additional file 1: methods S2 \[[@CR1]\]). The severity of fluid overload before initiation of renal replacement therapy as well as the cumulative fluid balance after initiation of renal replacement therapy were adjusted in all the multivariable regression models (Tables 3, 4, and 5 in \[[@CR1]\]).

Nevertheless, we would like to acknowledge that in clinical practice there are variety of factors that are likely to influence the clinical decision to determine the target UF^NET^ (e.g., starting fluid balance, ongoing fluid input/output, patient tolerance of fluid removal, severity of illness and organ edema, etc.) and further research is required to determine the relative contribution of these variables on UF^NET^ intensity and outcomes.

We completely agree with Dr. Li and colleagues that even though we adjusted for mean arterial pressure as well as the vasopressor dose in the models, we cannot exclude the possibility of residual confounding by hemodynamics on UF^NET^ intensity and outcomes. Although we could certainly perform a stratified analysis by mean arterial pressure, it would be difficult to fit models that account for continuous variation in blood pressure throughout the duration of renal replacement therapy and disentangle its association with UF^NET^ intensity and the outcome.
